Guide to Heart Impacts of Newer Diabetes Drugs

A recently published expert overview examines the cardiovascular benefits and risks of common diabetes drugs currently available in the United States, and lists which newer drug classes are beneficial for diabetes patients who already have indications of heart or blood vessel disease. Read more

Class of Diabetes Drug May Help Anemia

SGLT-2 inhibitors, a diabetes drug class that includes drugs like canagliflozin (Invokana) have been shown to be beneficial for patients who have both type 2 diabetes and chronic kidney disease in regards to developing anemia. Read more

Tirzepatide Shows Benefits in Type 2 Patients

Tirzepatide, a newer diabetes drug, has been shown to reduce patient hemoglobin A1c levels, as well as lowering body weight and improving insulin sensitivity markers in patients with type 2 diabetes.  Read more

Can Some Drugs that Lower Glucose Also Treat COVID-19?

Some drugs used to lower glucose in patients with diabetes, such as metformin, SGLT2 inhibitors, and sulfonylureas, might have beneficial effects on COVID-19, potentially affecting the risk of progression to severe disease and death. Read more

Sotagliflozin + Insulin for Type 1 Diabetes

SGLT-2 inhibitors like sotagliflozin are antihyperglycemic agents approved in the US for use in patients with type 2 diabetes. However, sotagliflozin is also approved for type 1 diabetes in Europe, and studies have shown that using sotagliflozin along with insulin has benefits in patients with type 1 diabetes. Read more

The “Medication Burden” and Type 2 Diabetes

People who have type 2 diabetes are likely to have complicated medication regimens that involve taking multiple drugs (also known as polypharmacy). Complex medication regimens are associated with worse health outcomes, as it is more difficult to follow a complicated treatment correctly, and there is increased risk for drug interactions. Read more

Researchers Seek Potential New Obesity & Type 2 Drug

GIP and GLP-1 are substances produced in the body’s digestive tract, and they play important roles in regulating body weight and food intake. A recently published study on their effects suggests that they may one day be used to develop drugs to treat obesity and type 2 diabetes. Read more

Diabetes Med May Treat Parkinson’s Disease

A clinical trial is being conducted in the United Kingdom to investigate whether the diabetes drug exenatide (Byetta) can be used to treat Parkinson’s Disease. Previous research has found that the risk for Parkinson’s is reduced in people who are treated with exenatide for their type 2 diabetes. Read more

Metformin Can Improve Surgical Recovery

Metformin, a commonly-prescribed diabetes drug, may have other benefits, researchers say. A study found that metformin use in patients with type 2 diabetes is associated with a reduced risk of rehospitalization and death following surgery. Read more

Start Combination Therapy Earlier, ADA Says

Metformin is the typical first-line treatment for people with type 2 diabetes, but the ADA suggests early combination therapy with other medications should be used in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease. Read more

More Evidence for Heart Benefits of Empagliflozin

Studies of diabetes drugs empagliflozin and dapagliflozin, both in the SGLT-2 inhibitor class, have shown they help reduce cardiovascular risk for diabetes patients. Now, researchers have found that empagliflozin is beneficial for the heart in people without diabetes as well. Read more

Once-Weekly Semaglutide May Assist with Weight Loss

The diabetes drug semaglutide, administered once-weekly subcutaneously and used in conjunction with lifestyle modifications, helped people with overweight or obesity achieve sustained, significant reductions in body weight. Read more

Diabetes Pharma Company Seeks to Reach More Young People with Type 1

Eli Lilly is expanding its existing type 1 diabetes partnership with Life for a Child, with the goal of supporting more than six times as many children in the next 10 years. Lilly plans to expand care to 150,000 young people with diabetes over the next decade, providing free medicine and equipment like reusable pens […]

Add-on Therapy Can Reduce Insulin Use for Type 2 Patients

Insulin is the mainstay treatment for patients with type 2 diabetes who also have beta-cell failure; however, some insulin regimens can be complicated to manage and may increase the risk of hypoglycemia. Now, researchers say that a simple add-on therapy with the GLP-1 Agonist medication albiglutide can reduce insulin use for patients with type 2 […]

Adding the Right Meds Early Can Reduce Heart Risks

High blood glucose levels can damage the heart’s nerves and blood vessels. This contributes to the development of heart diseases and eventual heart attacks. However, new research shows that starting patients on medication to prevent cardiovascular diseases when they are first diagnosed with diabetes can help reduce the risk. Read more

Daily Pill Could Help Optimize Insulin Use

New studies have investigated a once-daily pill that can optimize insulin therapy and reduce HbA1c among adults with type 1 diabetes. The pill, a novel liver-selective glucokinase activator, also known as TTP399, showed superior A1c reduction compared to placebo. Read more

How SGLT2 Inhibitors Affect Risk of Death

A recent study that aimed to review and assess all the current evidence regarding SGLT2 inhibitors and their impact on death from all causes in diabetes patients found that overall, this class of diabetes drug was associated with a reduction in all-cause mortality. Read more

Effect of Empagliflozin on Kidney Disease

Empagliflozin (sold under the brand name Jardiance) may reduce major adverse kidney events in some type 2 diabetes patients better than other medications, researchers say. The study used U.S. Department of Veterans Affairs (VA) data to assess the effectiveness of empagliflozin versus other antihyperglycemic drugs. Read more

Immunosuppressive Medication Shows Potential for Type 1 Treatment

Golimumab is a human antibody that is used as an immunosuppressive drug (brand name Simponi) and is approved for the treatment of several autoimmune conditions, including ulcerative colitis. Researchers investigated whether golimumab could preserve beta-cell function in young people newly diagnosed with type 1 diabetes. Read more

Could Diabetes Drug Sitagliptin Help Treat COVID-19?

Some research has suggested that inhibiting the protein DPP-4, which is produced by the human body, could provide benefit to patients infected with COVID-19. Sitagliptin is a diabetes drug in the DPP-4 inhibitor class that has also shown anti-inflammatory and immunoregulatory effects. Researchers investigated whether sitagliptin could help treat hospitalized COVID patients with type 2 […]